Yifan Pharmaceutical (002019.SZ): N-3C01 injection approved for clinical trials.

Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Xinzhu Biotechnology Co., Ltd. (referred to as "Hefei Xinzhu"), recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The approval allows Hefei Xinzhu to conduct clinical trials on the investigational new macromolecular drug N-3C01 injection (referred to as "N-3C01") for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer (NMIBC).